Belinda Palermo

Belinda Palermo

Auto-generated profile, based on publicly available information

Belinda Palermo

Unit of Tumor Immunology and Immunotherapy, Department of Research, Advanced Diagnostics and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1999 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
FSFederica Sallusto
Federica Sallusto
BPBelinda Palermo
Belinda Palermo
DLDanielle Lenig
Danielle Lenig
MMMinja Miettinen
Minja Miettinen
SMSampsa Matikainen
Sampsa Matikainen
ALAntonio Lanzavecchia
Antonio Lanzavecchia

21 August 2020 in Science
Verified
Journal Article
Closed access
AFAurélie Fluckiger
Aurélie Fluckiger
RDRomain Daillère
Romain Daillère
MSMohamed Sassi
Mohamed Sassi
BSBarbara Susanne Sixt
Barbara Susanne Sixt
PLPeng Liu
Peng Liu
LZLaurence Zitvogel
Laurence Zitvogel
Phages and cancer immunity: Gut bacteria are involved in the education of T cell immune responses, and the intestinal ecosystem influences anticancer immunity. Fluckiger et al. report microbial antigens that might cross-react with antigens associated with tumor cells. They found that a type of intestinal bacteria called enterococci harbor a bacteriophage that modulates immune responses. In mouse models, administration of enterococci containing the bacteriophage boosted T cell responses after treatment with chemotherapy or programmed cell death protein 1 (PD-1) blockade. In humans, the presence of the bacteriophage was associated with improved survival after PD-1 immunotherapy. A fraction of human T cells specific for naturally processed melanoma epitopes appeared to be able to recognize microbial peptides. This “molecular mimicry” may represent cross-reactivity between tumors and microbial antigens. Science , this issue p. 936

1 August 2001 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
BPBelinda Palermo
Belinda Palermo
RCRita Campanelli
Rita Campanelli
SGSilvia Garbelli
Silvia Garbelli
SMStefania Mantovani
Stefania Mantovani
ELErica Lantelme
Erica Lantelme
Claudia GiachinoClaudia Giachino
Claudia Giachino

6 October 2008 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
PNPaola Nisticò
Paola Nisticò
ICImerio Capone
Imerio Capone
BPBelinda Palermo
Belinda Palermo
DBDuilia Del Bello
Duilia Del Bello
VFVirginia Ferraresi
Virginia Ferraresi
EPEnrico Proietti
Enrico Proietti
Combination of chemotherapy with cancer vaccines is currently regarded as a potentially valuable therapeutic approach for the treatment of some metastatic tumors, but optimal modalities remain unknown. We designed a phase I/II pilot study for evaluating the effects of dacarbazine (DTIC) on the immune response in HLA‐A2+ disease‐free melanoma patients who received anticancer vaccination 1 day following chemotherapy (800 mg/mq i.v.). The vaccine, consisting of a combination of HLA‐A2 restricted melanoma antigen A (Melan‐A/MART‐1) and gp100 analog peptides (250 μg each, i.d.), was administered in combination or not with DTIC to 2 patient groups. The combined treatment is nontoxic. The comparative immune monitoring demonstrates that patients receiving DTIC 1 day before the vaccination have a significantly improved long‐lasting memory CD8+ T cell response. Of relevance, these CD8+ T cells recognize and lyse HLA‐A2+/Melan‐A+ tumor cell lines. Global transcriptional analysis of peripheral blood mononuclear cells (PBMC) revealed a DTIC‐induced activation of genes involved in cytokine production, leukocyte activation, immune response and cell motility that can favorably condition tumor antigen‐specific CD8+ T cell responses. This study represents a proof in humans of a chemotherapy‐induced enhancement of CD8+ memory T cell response to cancer vaccines, which opens new opportunities to design novel effective combined therapies improving cancer vaccination effectiveness.

14 September 2010 in Cancer Research
Verified
Journal Article
Open access
PDF file
BPBelinda Palermo
Belinda Palermo
DBDuilia Del Bello
Duilia Del Bello
ASAlessandra Sottini
Alessandra Sottini
FSFederico Serana
Federico Serana
CGClaudia Ghidini
Claudia Ghidini
PNPaola Nisticò
Paola Nisticò
Combination of chemotherapy and immunotherapy to increase the effectiveness of an antitumor immune response is currently regarded as an attractive antitumor strategy. In a pilot clinical trial, we have recently documented an increase of melanoma antigen A (Melan-A)–specific, tumor-reactive, long-lasting effector-memory CD8+ T cells after the administration of dacarbazine (DTIC) 1 day before peptide vaccination in melanoma patients. Global transcriptional analysis revealed a DTIC-induced activation of genes involved in the immune response and leukocyte activation. To identify the possible mechanisms underlying this improved immune response, we have compared the endogenous and the treatment-induced anti–Melan-A response at the clonal level in patients treated with the vaccine alone or with DTIC plus vaccine. We report a progressive widening of T-cell receptor (TCR) repertoire diversity, accompanied by high avidity and tumor reactivity, only in Melan-A–specific T-cell clones of patients treated with chemoimmunotherapy, with a trend toward longer survival. Differently, patients treated with vaccine alone showed a tendency to narrowing the TCR repertoire diversity, accompanied by a decrease of tumor lytic activity in one patient. Collectively, our findings indicate that DTIC plus vaccination shapes the TCR repertoire in terms of diversity and antitumor response, suggesting that this combined therapy could be effective in preventing melanoma relapse. Cancer Res; 70(18); 7084–92. ©2010 AACR.

19 July 2005 in Pigment Cell Research
Verified
Journal Article
Closed access
PDF file
SGSilvia Garbelli
Silvia Garbelli
SMStefania Mantovani
Stefania Mantovani
BPBelinda Palermo
Belinda Palermo
Claudia GiachinoClaudia Giachino
Claudia Giachino